The distinction between two primary @entity189 on the one hand and a metastatic disease on the other hand in @entity1 suffering from @entity4348 of the uterus and ovary is difficult. Exclusive histopathologic analysis appears to be insufficient and sometimes misleading. The @entity5 suppressor @entity983 was found to be important in early @entity4348 of the uterus. In this study, we screened @entity4348 of the uterus and ovary of 10 @entity1 for loss of heterozygosity using seven different microsatellite markers at 10q23.3 and for mutations in the entire coding region of @entity983 . Point mutations or microdeletions/insertions were found in six @entity1 . Allelic loss at 10q23.3 was detected in eight @entity1 . Based on conventional histology, a metastatic disease was diagnosed in seven @entity1 and a concomitant uterine and @entity43 in three @entity1 . After molecular analysis, the histopathologic diagnosis of three @entity1 had to be revised. Histopathology represents the standard method to process @entity5 specimens from these @entity1 . Nevertheless, mutation screen for @entity983 and LOH analysis at 10q23.3 provide helpful genetic tools to establish a correct final diagnosis, which is important in view of prognosis and therapeutic implications.

XXXX as a molecular marker to distinguish metastatic from primary @entity4348 of the ovary and uterus.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas'] @entity983 :: ('5728', 'Gene') :: ['PTEN'] @entity4348 :: ('MESH:D018269', 'Disease') :: ['neoplastic transformation in endometrioid carcinomas', 'synchronous endometrioid carcinomas']
@entity983 :: (5728,Gene) :: ['PTEN']
